The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
There is no doubt about the value of exogenous insulin for people with type 1 diabetes. The purpose of this commentary is to discuss emerging evidence that this may not be the case for the majority of people with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“While hyperglycaemia is associated with increased risks of death and cardiovascular disease [35,36], for the vast majority of patients with type 2 diabetes, there is no unequivocal evidence of benefit from insulin.”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 1×
“In general, published randomised controlled trial (RCT) data can only suggest that overall improvements in glycaemic control achieved through combination glucose-lowering therapies do not appear to decrease the risk of all-cause or cardiovascular mortality [33] or cancer [34].”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Insulin use in type 2 patients has also been associated with increased risk of overall cancer incidence [26] and cancer mortality [27].”
BackgroundSelf-citationSurvival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 1×
“Similarly, in an epidemiologic study of patients with type 2 diabetes treated in a UK primary care setting, those treated with insulin-based regimens had a 50% increased risk of dying than did comparable patients treated with a combination therapy of metformin plus sulfonylureas [16].”
BackgroundSelf-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · cited 1×
“Insulin is the most effective therapy for reducing hyperglycaemia and therefore remains high amongst the choices of add-on therapy for those patients whose HbA1c remains above recommended targets [3,4].”
BackgroundThree-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Smooke, S., Horwich, T. B., & Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.005 · Cited by 196
Cited by
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329
Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3042 · Cited by 203
Self-citationDiabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
“There have been concerns regarding whether exogenous insulin, especially insulin glargine, could increase the risk of cancer [53,54].”
Background
Metadata
- Authors
- Currie, C. J., & Johnson, J. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-11-21
- Volume
- 14
- Issue
- 1
- Pages
- 1-4
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2055789597
- Cited by
- 54
- References
- 10
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01469.x
- The paper
- Currie, C. J., & Johnson, J. A. (2012). The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01469.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.